FDA recommends approval of Tolvaptan for Hyponatremia

The FDA Advisory Committee on Cardiovascular and Renal Drugs has voted to recommend the approval of Otsuka’s V2-vasopressin receptor antagonist tolvaptan for the treatment of  hyponatremia.

Dopamine lead to Impulse-control disorders

Data presented at the Movement Disorder Society meeting show that treatment with dopamine agonists leads to compulsive behavior such as gambling, binge eating, impulsive buying and erratic sexual behavior

EMEA recommends prescribing changes for ergot derived dopamine agonists

The EMEA has recommended revisions to the prescribing information of ergot derived dopamine agonists following concerns about the development cardiac fibrosis in patients taking these drugs.

Vandas Tasimelteon (VEC-162) Improves Sleep in Patients with Chronic Insomnia

In a phase III trial in chronic insomnia Vanda Pharmaceutical’s melatonin agonist tasimelteon (VEC-162) met the primary endpoint of the trial and significantly improved sleep in adult patients.

Angiotensin II receptor antagonists slow rate of progressive aortic-root dilation in Marfans

Data published in this weeks NEJM show that angiotensin II receptor antagonists delay the progression of aortic root dissection in patients with Marfan’s syndrome